Evidence map›Paper›PMID 40507364›Full record

ArticleCancers2025

A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials.

Hope S Rugo, Binghe Xu, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Barinder Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hope S RugoHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.ORCID 0000-0001-6710-4814
Binghe XuDepartment of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Anandaroop DasguptaGilead Sciences, Inc., Foster City, CA 94404, USA.
Ankita KaushikGilead Sciences, Inc., Foster City, CA 94404, USA.
Wendy VerretGilead Sciences, Inc., Foster City, CA 94404, USA.
Barinder SinghPharmacoevidence, London SE1 0AS, UK.

Funding

Gilead Sciences, Inc. NA
6 · The paper itself

Abstract

backgroundThe patient-reported outcomes (PROs) of sacituzumab govitecan (SG) were compared with chemotherapy using two phase 3 trials (TROPiCS-02, EVER-132-002) involving patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.

methodsA meta-analysis was performed to compare change from baseline (CFB) scores and time-to-deterioration (TTD) between SG and chemotherapy using EORTC QLQ-C30 and EQ-5D-5L VAS in the overall, prior CDK4/6i-treated, and fast-progressor populations. Results of CFB and TTD analyses were summarized using hazard ratio (HR) and mean difference measures.

resultsStatistically significant improvement (

conclusionsSG significantly improved PROs versus chemotherapy for several subdomains of EORTC QLQ-C30 and EQ-5D-5L-VAS. The consistency of these results in the overall population and subgroups supports the generalizability of the meta-analytic evidence and reinforces the PRO benefits associated with SG versus chemotherapy.

Indexed as

EORTC QLQ-C30EQ-5D-5L VASEVER-132-002HR+/HER2 mBCmetastatic breast cancerpatient-reported outcomesquality of lifesacituzumab govitecanTROPiCS-02

Identifiers

PMID40507364
PMCPMC12153749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.